drugset / Trial / NCT00581243
Study Evaluating Safety and Tolerability of Ascending Multiple Dose of SLV-313 in Schizophrenia Patients
Phase 1
Terminated
32 enrolled
Wyeth is now a wholly owned subsidiary of Pfizer
Solvay Pharmaceuticals · collab
RandomizedSingle-groupTriple-blindTreatment
Summary
Randomized, inpatient, ascending multiple dose study given to subjects with schizophrenia and schizoaffective disorder to assess safety and tolerability.
Timeline
- Start
- 2008-01-01
- Primary completion
- 2008-05-01
- Completion
- 2008-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ADOPRAZINE | Small molecule | 2 mg | Oral |
| Subject | ADOPRAZINE | Small molecule | 5 mg | Oral |
| Subject | ADOPRAZINE | Small molecule | 10 mg | Oral |
Indications
No indication recorded.